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fasted rats and a rat model of type 2 diabetes. Furthermore, surgical de-
nervation of the pancreas dramatically improved ﬁrst-phase GSIS, gly-
cemic control, and β-cell survival in a murine diabetic model.
Decreased ﬁrst-phase GSIS may be a common insulin secretion pat-
tern during times of scarcity and type 2 diabetes. In this study, the au-
thors suggested an interesting hypothesis that beta cells in diabeticHypothalamic AMP-activated protein kinase (AMPK) is one of the
central regulators in energymetabolism. It was originally found that in-
hibition of hypothalamic AMPKby insulin, leptin or alpha-lipoic acid de-
creases food intake (Minokoshi et al., 2004; Kim et al., 2004), and
consequent studies have found that this mediates triiodothyronine's ef-
fect on thermogenesis in brown adipose tissue (Lopez et al., 2010).
AMPK is an enzyme activated during low cellular energy charge, and
AMPK in the hypothalamus may sense whole body energy status (Kim
et al., 2004).
Glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells
is biphasic, and suppression of the ﬁrst-phase GSIS is one of the most
characteristic ﬁndings of β-cell dysfunction in type 2 diabetes (Basu et
al., 1996;Weyer et al., 1999; Seino et al., 2011). Consistently, decreased
early insulin response is associated with post-prandial hyperglycemia
(Basu et al., 1996), and improvement in the ﬁrst-phase GSIS has been
proposed as a strategy for better glycemic control in type 2 diabetes.
However, at present, little is known on the mechanism underlying dia-
betes-related dysregulation of ﬁrst-phase GSIS.
In this issue of EBioMedicine, Kume and colleagues have identiﬁed a
novel role of hypothalamic AMPK in the regulation of ﬁrst-phase GSIS in
the pancreas (Kume et al., 2016). They focused on the relationship be-
tween fasting-dependent decrease in the ﬁrst-phase GSIS and β-cell
dysfunction in type 2 diabetes. Their study used human- and animal-
based experiments to reveal that prolonged fasting reduces ﬁrst-phase
GSIS by signaling via the brain-sympathetic nerve-β-cell axis. Reduced
ﬁrst-phase GSIS after prolonged fasting decreased and increased glu-
cose redistribution to peripheral tissues and brain, respectively, thereby
increasing the possibility tomaintain glucose supply to the brain at time
of refeeding after prolonged fasting. Interestingly, excitation of the hy-m.2016.10.038.
. This is an open access article underpothalamic AMPK-β-cell neural axis impaired ﬁrst-phase GSIS in both
individuals mistakenly sense that they are under conditions that
mimic prolonged fasting. This so-called “starvation diabetes” was ﬁrst
observed in 1960s (Unger et al., 1963), and Kume et al. have now solid-
iﬁed the notion that starvationmechanism is closely associatedwith the
pathogenesis of type 2 diabetes (Kume et al., 2016). During evolution,
mammals may have developed a well-organized system to regulate
blood glucose levels and to avoid serious hypoglycemia during starva-
tion. These mechanisms may be involved in the pathogenesis of type 2
diabetes. Therefore, identifying the mechanism(s) underlying starva-
tion diabetes may facilitate a better understanding of type 2 diabetes.
In the context of translation to clinical practice, the authors have
highlighted the therapeutic potency of pancreatic denervation for type
2 diabetes (Kume et al., 2016). Surprisingly, this surgical approach not
only improved glycemic control but also prevented future β-cell loss.
This suggests a novel possibility that hyperactivation of hypothalamic
AMPK by fasting leads to both acute and chronic impairment of pancre-
atic β cell function, even though the mechanism of diabetes prevention
by pancreatic denervation remains to be determined.
It also remains to be determined whether the present ﬁndings
can translate to the management of type 2 diabetes. Interestingly,
similar approaches are currently approved as therapeutic interventions
in other diseases, including bariatric surgery for severe obesity
(Mingrone et al., 2012) and renal denervation for hypertension (Esler
et al., 2010). If pancreatic denervation can be technically applied to
human type 2 diabetic patients, this surgical approach may become a
novel therapeutic strategy to improve glycemic control by improving
β-cell function and survival. Again, the increasing incidence of type 2 di-
abetes is a global public health problem.We hope thatwewill be able to
combat type 2 diabetes by continued efforts to fully understand disease
pathogenesis.Disclosure
The author declared no conﬂicts of interest.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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